VISCHER represents the sellers of Redvax GmbH, in Schlieren in its sale to Pfizer. Redvax is a spin-off from Redbiotec AG, a privately held Swiss biopharmaceutical company, based in Zurich-Schlieren. Redvax develops a preclinical human cytomegalovirus (CMV) vaccine candidate, a herpes virus. A vaccine could prevent a CMV infection during pregnancy and of passing the infection on to the unborn child. The VISCHER-team is led by Matthias Staehelin (Corporate) und Nadia Tarolli (Tax) with Dania Salvsiberg-Schneider, Matthias Kuster, Sara Ianni (all Corporate) and Melanie Knüsel, Meral Korkmaz and Isabelle Stebler (all Tax).